# US 2024/0189231 A1 · Lipid vesicle compositions with penetration enhancing agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189231 A1
- Document ID: US20240189231A1
- Status: Published application
- Kind: A1
- Application number: 18/470,334
- Filed: 2023-09-19
- Published: 2024-06-13
- Earliest claimed: 2019-09-23
- Assignees: Dds Research Inc.
- Applicants: DDS Research Inc.
- Inventors: Marianna FOLDVARI
- Web page: https://patentgrep.com/patent/US20240189231A1

## CPC

- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 8/14: Liposomes; Vesicles
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/1273: Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
- A61K 47/08: containing oxygen, {e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides}
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/14: Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A61K 47/186: {Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide}
- A61K 47/22: Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/44: Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin (synthetic glycerides, e.g. medium-chain triglycerides, A61K47/14)
- A61P 17/00: Drugs for dermatological disorders
- A61Q 19/08: Anti-ageing preparations
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

The present application is related to a pharmaceutical composition a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more surfactants; one or more compounds; and one or more penetration enhancing agents. The one or more penetration enhancing agents include one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of about 10 or less, alone or combination with one or more penetration enhancing agents selected from one or more of terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof. The present application is also related to a pharmaceutical composition comprising a biphasic lipid vesicle comprising a lipid bilayer comprising vesicle forming lipids; an oil-in-water emulsion stabilized by one or more polycationic surfactants; and one or more compounds.

## Claims

### Claim at position 1

-20. (canceled)

### Claim 21

A biphasic lipid vesicle composition comprising:
(a) lipid vesicles each comprising a lipid bilayer comprising vesicle forming lipids,
(b) an oil-in-water emulsion entrapped in the biphasic lipid vesicles, and stabilized by a surfactant;
(c) a penetration enhancing agent entrapped in the lipid bilayer or the oil-in-water emulsion;
wherein the penetration enhancing agent (i) comprises a non-ionic surfactant having a hydrophilic-lipophilic balance (HLB) of 10 or less; and (ii) is selected from the group consisting of: diethylene glycol monooleyl ether, sorbitan monopalmitate, and polyoxy-ethylene (4) dilaurate.

### Claim 22 (depends on 21)

The composition of claim 21, wherein the penetration enhancing agent is entrapped in the oil-in-water emulsion.

### Claim 23 (depends on 21)

The composition of claim 21, wherein the penetration enhancing agent is entrapped in the lipid bilayer and the oil-in-water emulsion.

### Claim 24 (depends on 21)

The biphasic lipid vesicle composition of claim 21, wherein the penetration enhancing agent is diethylene glycol monooleyl ether.

### Claim 25 (depends on 21)

The biphasic lipid vesicle composition of claim 21, wherein the penetration enhancing agent is PEG-4 dilaurate.

### Claim 26 (depends on 21)

The biphasic lipid vesicle composition of claim 21, wherein the biphasic lipid vesicle composition further comprises an additional penetration enhancing agent selected from one or more terpenes, alkaloids, salicylate derivatives, and polycationic surfactants and combinations thereof.

### Claim 27 (depends on 26)

The biphasic lipid vesicle composition of claim 26, wherein the one or more terpenes are selected from one or more of eugenol, d-limonene, menthol, menthone, farnesol, neridol, camphor, nerol and thymol, and combinations thereof.

### Claim 28 (depends on 26)

The biphasic lipid vesicle composition of claim 26, wherein the one or more salicylate derivatives is selected from one or more of ethyl salicylate, salicylic acid, acetylsalicylic acid and trolamine salicylate and combinations thereof.

### Claim 29 (depends on 26)

The biphasic lipid vesicle composition of claim 26, wherein the one or more alkaloids are selected from piperine, lobeline, caffeine, theobromine theophylline, nicotine, colchicine, N-methyl pyrrolidone, hygrine, capsaicin, berberine, sanguinarine, histamine and/or pilocarpine.

### Claim 30 (depends on 26)

The biphasic lipid vesicle composition of claim 26, wherein the polycationic surfactants are one or more gemini cationic surfactants and the one or more gemini cationic surfactants are of a quaternary ammonium type.

### Claim 31 (depends on 26)

The biphasic lipid vesicle composition of claim 26, wherein the polycationic surfactants are polycationic amino acids.

### Claim 32 (depends on 21)

The biphasic lipid vesicle composition of claim 21, wherein the oil-in-water emulsion of the biphasic lipid vesicles is stabilized by one or more surfactants or more surfactants selected from polyoxyethylene (10) cetyl ether and polysorbate 80.

### Claim 33 (depends on 21)

The biphasic lipid vesicle composition of claim 21, wherein the vesicle forming lipids are selected from one or more of phospholipids, glycolipids, lecithins, and/or ceramides.

### Claim 34 (depends on 33)

The biphasic lipid vesicle composition of claim 33, wherein the one or more of phospholipids, glycolipids, lecithins, and/or ceramides comprises phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, cardiolipin, phosphatidic acid, and cerebroside.

### Claim 35 (depends on 21)

The biphasic lipid vesicle composition of claim 21, further comprising one or more compounds entrapped in the lipid bilayer and/or the oil-in-water emulsion.

### Claim 36 (depends on 35)

The biphasic lipid vesicle composition of claim 35, wherein the one or more compounds are entrapped in oil-in-water emulsion of the biphasic lipid vesicle, lipid bilayer of the biphasic lipid vesicle or both the oil-in-water emulsion the lipid bilayer.

### Claim 37 (depends on 35)

The biphasic lipid vesicle composition of claim 35, wherein the one or more compounds are selected from small molecules, proteins, peptides, carbohydrates, nucleic acids, vaccine antigens, and/or plant extracts.

### Claim 38 (depends on 37)

The biphasic lipid vesicle composition of claim 37, wherein the small molecules are selected from the group consisting of prostaglandins, anesthetic agents, analgesics or sedatives, cardioactive medication, adrenergic blockers, estrogens, progestogens, antihistamines, antiviral agents, vitamins, anti-inflammatory agents, antifungal agents, corticosteroids, anti-infectives, antibacterial agents, dermatological agents, medication for the treatment of nausea and sickness, amino acids, short peptides, carbohydrates, natural compounds and a combination thereof.

### Claim 39 (depends on 21)

A method of preparing biphasic lipid vesicle composition of claim 21, comprising:
(a) preparing an oil-in-water emulsion by mixing oil components of the oil-in-water emulsion with aqueous components of the oil-in-water emulsion;
(b) solubilizing vesicle forming lipids in an acceptable solvent other than water;
(c) adding one or more penetration enhancing agents to the oil components and/or the aqueous components of step a), or the solubilized vesicle forming lipids of step b), wherein the one or more penetration enhancing agents are one or more non-ionic surfactants having a hydrophilic-lipophilic balance (HLB) of 10 or less;
(d) adding the oil-in-water emulsion to the solubilized vesicle forming lipids; and
(e) mixing the oil-in-water emulsion and the solubilized vesicle forming lipids under mixing conditions effective to form the biphasic lipid vesicles comprising a lipid bilayer, the oil-in-water emulsion entrapped in the biphasic lipid vesicles, and the one or more penetration enhancing agents entrapped in the oil-in-water emulsion and/or the lipid bilayer.

### Claim 40 (depends on 39)

The method of claim 39, further comprising adding one or more compounds in (b).
